Abstract
The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.
Original language | English (US) |
---|---|
Pages (from-to) | 65-70 |
Number of pages | 6 |
Journal | Investigational New Drugs |
Volume | 1 |
Issue number | 1 |
DOIs | |
State | Published - Mar 1983 |
Externally published | Yes |
Keywords
- Hodgkin's disease
- mitoxantrone
- non-Hodgkin's lymphoma
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)